Status:
COMPLETED
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
Lead Sponsor:
Tanabe Pharma Corporation
Conditions:
Crohn's Disease
Eligibility:
All Genders
16-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the efficacy, safety and pharmacokinetics after administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an insufficient response ...
Eligibility Criteria
Inclusion
- Patients with Crohn's disease
- Patients who have relapsed with symptoms associated with Crohn's disease within 8 weeks in spite of maintenance treatment with 5mg/kg REMICADE every 8 weeks, and who are judged to be showing an insufficient response to the previous treatment by their physician
Exclusion
- Severe intestinal strictures (which may have an effect on the number of loose stools or diarrhea or dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy), a diagnosis of short bowel syndrome, or previous stoma surgery
- The presence of significant internal fistula (possibility that surgery might be needed, etc.) is confirmed
- A history of a serious infusion reaction to REMICADE
- Pregnant, lactating, and probably pregnant women
- Patients who have participated in other trials and have been administered other investigational products within 12 weeks before consent
- Patients judged to be inadequate to participate in this study by their physician
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00805766
Start Date
December 1 2008
End Date
July 1 2010
Last Update
January 7 2026
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational site
Hokkaido, Japan
2
Investigational site
Kansai, Japan
3
Investigational site
Kanto, Japan
4
Investigational site
Kyushu, Japan